Clinical Trials Browser

Thoracic Neoplasms

NCT03256981 2023-12-26

HALT

Phase 2/3 Unknown

113 enrolled

Thoracic

NSCLC

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Phase 2/3 Unknown

20 enrolled

Thoracic

NSCLC

NCT05994339 2023-08-29

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Phase 2/3 Unknown

40 enrolled

Thoracic

Lung Neoplasms

NCT03380468 2023-07-20

ECTOP-1004

Phase 2/3 Unknown

300 enrolled

Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT05661240 2022-12-22

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Phase 2/3 Unknown

348 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

Phase 2/3 Unknown

150 enrolled

Thoracic

NSCLC

NCT04942275 2022-09-19

PEGASUS

Phase 2/3 Unknown

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Phase 2/3 Unknown

90 enrolled

Thoracic

NSCLC

NCT04968002 2021-07-20

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

Phase 2/3 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04874844 2021-05-10

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Phase 2/3 Unknown

420 enrolled

Thoracic

NSCLC

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

700 enrolled

Thoracic

Nonsquamous Non-small Cell Lung Cancer

NCT04702009 2021-01-08

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Phase 2/3 Unknown

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03288870 2020-10-29

DOMINUS

Phase 2/3 Unknown

218 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Phase 2/3 Unknown

313 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02416739 2020-01-27

Anticancer Activity of Nicotinamide on Lung Cancer

Phase 2/3 Unknown

110 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04192682 2020-01-06

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Phase 2/3 Unknown

40 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02759783 2019-08-21

CORE

Phase 2/3 Unknown

245 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

NCT03732482 2019-01-29

Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases

Phase 2/3 Unknown

400 enrolled

Thoracic

Non Small Cell Lung Cancer Metastatic

NCT01407822 2018-09-11

EMERGING

Phase 2/3 Unknown

72 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03384667 2018-02-28

Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer

Phase 2/3 Unknown

96 enrolled

Thoracic

Lung Neoplasms

NCT01782287 2017-10-12

Proteome-based Immunotherapy of Lung Cancer Brain Metastases

Phase 2/3 Unknown

60 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT03074864 2017-03-09

TREND

Phase 2/3 Unknown

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Unknown

110 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02802540 2016-08-31

Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients

Phase 2/3 Unknown

78 enrolled

Thoracic

Anorexia, Cachexia, Carcinoma, Non-Small-Cell Lung

NCT02780778 2016-05-23

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Phase 2/3 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02772107 2016-05-17

Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer

Phase 2/3 Unknown

132 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02393664 2015-07-03

Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection

Phase 2/3 Unknown

300 enrolled

Thoracic

Lung Neoplasms

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Phase 2/3 Unknown

380 enrolled

Thoracic

NSCLC

NCT02350361 2015-01-29

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Phase 2/3 Unknown

60 enrolled

Thoracic

Lung Neoplasms

NCT02338011 2015-01-26

EGFR

Phase 2/3 Unknown

210 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00030641 2014-01-06

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Phase 2/3 Unknown

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00022009 2013-09-20

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2/3 Unknown

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01802021 2013-03-01

QSYQT

Phase 2/3 Unknown

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01731548 2013-01-23

A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer

Phase 2/3 Unknown

500 enrolled

Thoracic

Lung Neoplasms

NCT01481259 2012-07-03

Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01048970 2010-01-14

Effect on the Nutritional and Inflammatory Status of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement in Patients With Advanced Lung Cancer

Phase 2/3 Unknown

120 enrolled

Thoracic

Lung Neoplasms, Weight Loss

NCT00168896 2006-02-14

A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

Phase 2/3 Unknown

286 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

ParaSOL

HALT

The Efficacy and Safety of KN046 Combined With Axitinib

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

ECTOP-1004

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

PEGASUS

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

DOMINUS

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Anticancer Activity of Nicotinamide on Lung Cancer

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

CORE

Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases

EMERGING

Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer

Proteome-based Immunotherapy of Lung Cancer Brain Metastases

TREND

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer

Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection

Gefitinib Combined With Thalidomide to Treat NSCLC

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

EGFR

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

QSYQT

A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer

Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer

Effect on the Nutritional and Inflammatory Status of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement in Patients With Advanced Lung Cancer

A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage